Genetic testing in women diagnosed with breast cancer decreases cost of care nationwide

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the US by about $50 million (about 2 percent of the overall costs in the first year).

Leave a Reply

Your email address will not be published. Required fields are marked *